Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» bispecific antibodies
bispecific antibodies
Biotheus, BioNTech Partner on Oncology Bispecific Antibody
Biotheus, BioNTech Partner on Oncology Bispecific Antibody
Contract Pharma
BioNTech
bispecific antibodies
Biotheus
Flag link:
Amgen’s T-Cell Engager Shows Phase II Promise in Tough to Treat Lung Cancer
Amgen’s T-Cell Engager Shows Phase II Promise in Tough to Treat Lung Cancer
BioSpace
Amgen
bispecific antibodies
T-cell engager
tarlatamab
clinical trials
Flag link:
Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific
Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific
Fierce Biotech
Roche
diabetic retinopathy
solid tumors
bispecific antibodies
Flag link:
Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
Clinical Trials Arena
Regeneron
clinical trials
bispecific antibodies
linvoseltamab
Flag link:
Janssen granted additional European Commission approval for bispecific antibody
Janssen granted additional European Commission approval for bispecific antibody
Biopharma Reporter
Janssen
JNJ
bispecific antibodies
Europe
relapsed or refractory multiple myeloma
Flag link:
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Fierce Biotech
Regeneron
prostate cancer
clinical trials
patient deaths
REGN5678
bispecific antibodies
Flag link:
Takeda adds another F-Star collab to constellation, this time for $1B in biobucks
Takeda adds another F-Star collab to constellation, this time for $1B in biobucks
Fierce Biotech
Takeda
F-star Therapeutics
bispecific antibodies
immuno-oncology
Flag link:
AbbVie, Genmab Bi-Specific Lymphoma Data Tee Up Potential Challenge to Roche Drug
AbbVie, Genmab Bi-Specific Lymphoma Data Tee Up Potential Challenge to Roche Drug
BioSpace
AbbVie
Genmab
Roche
follicular lymphoma
bispecific antibodies
epcoritamab
Lunsumio
Flag link:
J&J quietly punts a pair of early-stage bispecifics for solid tumors
J&J quietly punts a pair of early-stage bispecifics for solid tumors
Endpoints
JNJ
bispecific antibodies
solid tumors
Flag link:
FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate
FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate
Endpoints
FDA
priority review
Pfizer
Prevnar 20
vaccines
Roche
bispecific antibodies
glofitamab
lymphoma
Flag link:
AbbVie's Roche-rivaling blood cancer bispecific gets FDA priority review, triggering Genmab payday
AbbVie's Roche-rivaling blood cancer bispecific gets FDA priority review, triggering Genmab payday
Fierce Biotech
AbbVie
Genmab
FDA
Roche
epcoritamab
bispecific antibodies
relapsed or refractory large B-cell lymphoma
Flag link:
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Fierce Pharma
Roche
Genentech
Vabysmo
bispecific antibodies
Eylea
Flag link:
Buy now, pay later: Jazz hands over $50M for Zymeworks' phase 3 HER2-directed bispecific
Buy now, pay later: Jazz hands over $50M for Zymeworks' phase 3 HER2-directed bispecific
Fierce Biotech
Jazz Pharmaceuticals
Zymeworks
HER2 inhbitor
bispecific antibodies
Flag link:
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
BioPharma Dive
Seagen
Merck
Lava Therapeutics
bispecific antibodies
LAVA-1223
Flag link:
J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering
J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering
Fierce Pharma
JNJ
Europe
bispecific antibodies
Multiple Myeloma
Tecvayli
teclistamab
Flag link:
Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets in light of data and competition
Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets in light of data and competition
Fierce Biotech
Amgen
BCMA
PSMA
Multiple Myeloma
bispecific antibodies
Flag link:
Following bispecific deal with Pfizer, quiet California biotech raises $65M, heads to the clinic
Following bispecific deal with Pfizer, quiet California biotech raises $65M, heads to the clinic
Endpoints
Dren Bio
Pfizer
bispecific antibodies
Flag link:
ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma
ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma
Pharmaforum
JNJ
Pfizer
ASCO 2022
bispecific antibodies
relapsed or refractory multiple myeloma
Flag link:
Roche trumpets new glofitamab data in lymphoma at ASCO
Roche trumpets new glofitamab data in lymphoma at ASCO
Pharmaforum
Roche
ASCO 2022
glofitamab
lymphoma
bispecific antibodies
Flag link:
Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs
Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs
MedCity News
Rondo Therapeutics
bispecific antibodies
solid tumors
cancer
funding
Flag link:
Pages
1
2
3
4
next ›
last »